Inactive Instrument

Other languages IRLAB Therapeutics AB (publ) Nasdaq Stockholm

Equities

SE0012675361

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

IRLAB appoints Kristina Torfgard as new CEO	May. 28
IRLAB presents at Redeye Growth Day 30 May	May. 28
Sweden’s IRLAB Therapeutics Names New CEO	May. 27
IRLAB appoints Kristina Torfgård as new CEO	May. 27
IRLAB Therapeutics AB Announces CEO Changes, Effective from August 1, 2024	May. 27
IRLAB Therapeutics AB Strengthens Liquidity by Drawing SEK 25 Million on A Previously Secured Loan Facility	May. 23
IRLAB strengthens its liquidity by drawing SEK 25 million on a previously secured loan facility	May. 23
Report from the Annual General Meeting 2024 of IRLAB Therapeutics AB	May. 22
IRLAB Therapeutics AB Administers the First Dose in A Phase I Clinical Trial with the Drug Candidate Irl757	May. 22
IRLAB has administered the first dose in a Phase I clinical trial with the drug candidate IRL757	May. 22
IRLAB broadcasts the annual general meeting live	May. 22
IRLAB presents at ABGSC Investor Days	May. 21
Transcript : IRLAB Therapeutics AB, Q1 2024 Earnings Call, May 08, 2024	May. 08
IRLAB publishes interim report for the period January-March 2024	May. 08
IRLAB Therapeutics AB Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 08
IRLAB Therapeutics AB and McQuade Center for Strategic Research and Development, LLC Enter into Development Collaboration for IRL757 as Novel Treatment for Apathy	May. 07
IRLAB Enters a Development Collaboration for IRL757 as a Novel Treatment for Apathy	May. 07
IRLAB Has Received Approval from the Swedish Medical Products Agency to Conduct a Phase I Study of the Drug Candidate IRL757	May. 06
IRLAB has received approval from the Swedish Medical Products Agency to conduct a Phase I study of the drug candidate IRL757	May. 06
IRLAB: Invitation to the interim report for Q1 2024 presentation and webcast	May. 06

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages IRLAB Therapeutics AB (publ) Nasdaq Stockholm

Equities

SE0012675361

Other languages

Filters